IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
- Written by PR Newswire
NANJING, China and SINGAPORE, Aug. 14, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based immune cell engineering and cell therapy company.
This acquisition marks a step in IASO Bio's globalization strategy, integrating MediSix's differentiated...














